Enzychem Lifesciences Corporation
8
0
0
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 8 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (8)
Determine the Dose-dependent Efficacy and Safety of EC-18 in Patients With Moderate to Severe Atopic Dermatitis
Role: lead
Management of Severe Chemotherapy-induced Neutropenia in Advanced Breast Cancer
Role: lead
EC-18 for Oral Mucositis in Patients With Concomitant Chemoirradiation
Role: lead
To Evaluate Safety and Efficacy of EC-18 in COVID-19 Infection to Pneumonia
Role: lead
Prevention of COVID-19 Infection to Severe Pneumonia or ARDS
Role: lead
Evaluation of the Food Effect on the Safety, Tolerability, PK of EC-18 After Oral Administration in Healthy Volunteers
Role: lead
Study to Evaluate the Safety, Tolerability and PK of EC-18 After Oral Administration in Healthy Volunteers
Role: lead
A Safety and PK Study of EC-18 in Healthy Subjects
Role: lead
All 8 trials loaded